


## WHAT IS CLAIMED IS:

1. A compound according to formula (I):



wherein:


A)  $R^1$  is  $-L^1-[C(R^{6a}R^{6b})]_mR^7$ , wherein:

- a)  $L^1$  is selected from the group consisting of covalent bond,  $-O-$ ,  $-S-$ ,  $-N-$ ,  $-CO_2-$ ,  $-CO-$ ,  $-OCO_2-$ ,  $-SO-$ ,  $-SO_2-$ ,  $-CSN(R^8)-$ ,  $-CON(R^8)O-$ ,  $-CON(R^8)-$ ,  $-OCON(R^8)-$ ; wherein  $R^8$  is hydrogen or substituted or unsubstituted  $C_1-C_5$  alkyl;
- b)  $R^{6a}$  and  $R^{6b}$  are each independently selected from the group consisting of hydrogen,  $-OR^9$ ,  $-N(R^9)_2$ ,  $-CO_2R^9$ ,  $-CON(R^9)_2$ ,  $-NHCOR^9$ ,  $-NHCO_2R^9$ ,  $=NR^9$ ,  $-R^9$ , and mixtures thereof; wherein each  $R^9$  is independently selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1-C_5$  alkyl, and substituted or unsubstituted aryl or alkylenearyl; or two  $R^9$  units can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms;
- c)  $m$  is an index selected from 0 to 5;
- d)  $R^7$  is selected from the group consisting of nil, hydrogen, substituted or unsubstituted  $C_1-C_{10}$  alkyl, substituted or unsubstituted  $C_1-C_{10}$  heteroalkyl, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; or
- e)  $R^7$  and a  $R^9$  can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms;

B)  $R^2$  is  $-(CH_2)_j-L^2-[C(R^{11a}R^{11b})]_gR^{12}$ , wherein:

- a)  $j$  is an index selected from 0 to 5;
  - b)  $L^2$  is selected from the group consisting of covalent bond, -O-, -S-, -N-, -CO<sub>2</sub>-, -CO-, -OCO<sub>2</sub>-, -SO-, -SO<sub>2</sub>-, -CSN(R<sup>10</sup>)-, -CON(R<sup>10</sup>)-, -CON(R<sup>10</sup>)O-, -OCON(R<sup>10</sup>)-, wherein R<sup>10</sup> is hydrogen or substituted or unsubstituted C<sub>1</sub>-C<sub>5</sub> alkyl;
  - c) R<sup>11a</sup> and R<sup>11b</sup> are each independently selected from the group consisting of hydrogen, -OR<sup>13</sup>, -N(R<sup>13</sup>)<sub>2</sub>, -CO<sub>2</sub>R<sup>13</sup>, -CON(R<sup>13</sup>)<sub>2</sub>, -NHCOR<sup>13</sup>, -NHCO<sub>2</sub>R<sup>13</sup>, =NR<sup>13</sup>, -R<sup>13</sup>, and mixtures thereof; wherein each R<sup>13</sup> is independently selected from the group consisting of hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>5</sub> alkyl, and substituted or unsubstituted aryl or alkylenearyl; or two R<sup>13</sup> units can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms;
  - d)  $g$  is an index selected from 0 to 5;
  - e) R<sup>12</sup> is selected from the group consisting of nil, hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; or
  - f) R<sup>12</sup> and a R<sup>13</sup> can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms;
- C) R<sup>3</sup> is -(CH<sub>2</sub>)<sub>n</sub>-L<sup>3</sup>-R<sup>16</sup>, wherein:
- a)  $n$  is an index selected from 0 to 5;
  - b) L<sup>3</sup> is selected from covalent bond, -O-, -S-, -N-, -CO<sub>2</sub>-, -CO-, -OCO<sub>2</sub>-, -SO-, -SO<sub>2</sub>-, -CSNH-, -CONH-, -OCONH-;
  - c) R<sup>16</sup> is selected from the group consisting of hydrogen, substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> heteroalkyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl;
- D) R<sup>4a</sup>, R<sup>4b</sup>, R<sup>4c</sup> and R<sup>5</sup> are each independently selected from hydrogen or substituted unit; or
- E) R<sup>2</sup> and R<sup>4a</sup>, R<sup>4a</sup> and R<sup>4b</sup>, R<sup>1</sup> and R<sup>2</sup>, or R<sup>1</sup> and R<sup>3</sup> can be taken together to form a substituted or unsubstituted carbocyclic or heterocyclic ring comprising from 3 to 7 atoms.

2. The compound of claim 1 having the formula (II):



3. The compound of Claim 2, wherein:
  - a)  $j$  is 0;
  - b)  $L^2$  is  $-\text{CON}(\text{R}^{10})-$ ; and
  - c)  $g$  is 0.
4. The compound of Claim 3, wherein  $\text{R}^3$  is hydrogen.
5. The compound of Claim 4, wherein  $L^1$  is selected from the group consisting of  $-\text{CO}_2-$ ,  $-\text{CO}-$ ,  $-\text{SO}_2-$ , and  $-\text{CON}(\text{R}^8)-$ .
6. The compound of Claim 2, wherein:
  - a)  $j$  is 0;
  - b)  $L^2$  is  $-\text{CON}(\text{R}^{10})-$ ; and
  - c)  $g$  is 1.
7. The compound of Claim 6, wherein  $\text{R}^3$  is hydrogen.
8. The compound of Claim 7, wherein at least  $\text{R}^{11a}$  or  $\text{R}^{11b}$  is  $-\text{CONH}_2$ .
9. The compound of Claim 2, wherein  $\text{R}^2$  is hydrogen.
10. The compound of Claim 9, wherein  $L^1$  is  $-\text{SO}_2-$ .
11. The compound of Claim 10, wherein  $L^3$  is selected from covalent bond,  $-\text{CO}-$ , and  $-\text{CO}_2$ .
12. The compound of Claim 10, wherein  $\text{R}^3$  is hydrogen.

13. The compound of Claim 10, wherein:
- a)  $m$  is an index selected from 1 and 2; and
  - b)  $R^7$  is substituted or unsubstituted phenyl.
14. The compound of Claim 2, wherein  $R^3$  is benzyl.
15. The compound of Claim 14, wherein:
- a)  $j$  is 0; and
  - b)  $L^2$  is selected from  $-CO_2-$  and  $-CON(R^8)-$ .
16. The compound of Claim 2, wherein:
- a)  $j$  is 0;
  - b)  $L^1$  is  $-CO-$ ;
  - c)  $m$  is 1;
  - d)  $R^{6a}$  or  $R^{6b}$  is at least  $-NHCO_2R^9$ ; and
  - e)  $L^2$  is  $-CON(R^8)-$ ;
17. The compound of Claim 2, wherein:
- a)  $j$  is 0;
  - b)  $L^1$  is  $-CO-$ ;
  - c)  $m$  is 1;
  - d)  $R^{6a}$  or  $R^{6b}$  is at least  $-NHCO_2R^9$ ; and
  - e)  $R^7$  is benzyl.
18. The compound of Claim 1, wherein the compound is selected from the group consisting of: (R)-[1-Methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (R)-[1-Methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid benzyl ester; (S)-[1-Methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid benzyl ester; (S)-[1-Methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (R)-[1-Pentylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (R)-[1-Benzylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[1-Benzylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (R)-[1-(2-Morpholin-4-yl-ethylcarbamoyl)-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester;

(S)-[1-Pentylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[4-(2-Hexanoylamino-2-methylcarbamoyl-ethyl)-phenyl]-sulfamic acid; (S)-{4-[2-Methylcarbamoyl-2-(toluene-4-sulfonylamino)-ethyl]-phenyl}-sulfamic acid; (R)-{4-[2-Methylcarbamoyl-2-(3-phenyl-propionylamino)-ethyl]-phenyl}-sulfamic acid; (S)-{4-[2-Methylcarbamoyl-2-(3-phenyl-propionylamino)-ethyl]-phenyl}-sulfamic acid; (S)-[1-(2-Methoxy-ethylcarbamoyl)-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[1-(2-Ethoxy-ethylcarbamoyl)-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[1-(2-Ethylsulfanyl-ethylcarbamoyl)-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[1-(4-Phenyl-butylcarbamoyl)-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-3-[2-tert-Butoxycarbonylamino-3-(4-sulfoamino-phenyl)-propionylamino]-propionic acid; (S)-{4-[2-(3-Benzyl-ureido)-2-methylcarbamoyl-ethyl]-phenyl}-sulfamic acid; (S)-(4-{2-[3-(2-Methoxy-phenyl)-ureido]-2-methylcarbamoyl-ethyl}-phenyl)-sulfamic acid; (S)-[4-(2-Benzenesulfonylamino-2-methylcarbamoyl-ethyl)-phenyl]-sulfamic acid; (S)-{4-[2-(4-Methoxy-benzenesulfonylamino)-2-methylcarbamoyl-ethyl]-phenyl}-sulfamic acid; (S)-{4-[2-Methylcarbamoyl-2-(naphthalene-1-sulfonylamino)-ethyl]-phenyl}-sulfamic acid; (S)-[1-(Benzyl-methyl-carbamoyl)-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[1-(2-Methyl-5-phenyl-2H-pyrazol-3-ylcarbamoyl)-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[1-Phenylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-[1-Dibenzylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-4-[1-Methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethylcarbamoyl]-piperidine-1-carboxylic acid tert-butyl ester; (S)-[4-(2-Benzoylamino-2-methylcarbamoyl-ethyl)-phenyl]-sulfamic acid; (S)-[1-Dimethylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; (S)-(4-{2-Methylcarbamoyl-2-[(pyridine-3-carbonyl)-amino]-ethyl}-phenyl)-sulfamic acid; (S)-[4-(2-Methylcarbamoyl-2-phenylacetyl-amino)-ethyl]-phenyl]-sulfamic acid; (S)-(4-{2-Methylcarbamoyl-2-[(naphthalene-1-carbonyl)-amino]-ethyl}-phenyl)-sulfamic acid; (S)-{4-[2-(Cyclopentanecarbonyl-amino)-2-methylcarbamoyl-ethyl]-phenyl}-sulfamic acid; (S)-(4-{2-Benzylcarbamoyl-2-[2-(4-propyl-phenyl)-acetyl-amino]-ethyl}-phenyl)-sulfamic acid; (S)-(4-{2-[3-(3-Acetylsulfamoyl-phenyl)-propionylamino]-2-methylcarbamoyl-ethyl}-phenyl)-sulfamic acid; (S)-{4-[2-Benzoylamino-2-(1-carbamoyl-2-(S)-phenyl-ethylcarbamoyl)-ethyl]-phenyl}-sulfamic acid; (S)-[1-[1-Carbamoyl-2-(4-hydroxy-phenyl)-ethylcarbamoyl]-2-(S)-(4-sulfoamino-phenyl)-ethyl]-carbamic acid tert-butyl ester; [4-(2-{(tert-Butoxycarbonyl)[(4-methylphenyl)sulfonyl]amino}ethyl)phenyl]sulfamic acid; (4-{2-[Benzyl-(toluene-4-sulfonyl)-amino]-ethyl}-phenyl)sulfamic acid; (4-{2-[(3-Methyl-but-2-enyl)-(toluene-4-sulfonyl)-amino]-ethyl}-phenyl)sulfamic acid; (4-{2-[(3-Methyl-butyl)-(toluene-4-sulfonyl)-amino]-ethyl}-

phenyl)-sulfamic acid; [[2-(4-Sulfoamino-phenyl)-ethyl]-(toluene-4-sulfonyl)-amino]-acetic acid ethyl ester; [[2-(4-Sulfoamino-phenyl)-ethyl]-(toluene-4-sulfonyl)-amino]-acetic acid; [4-(2-{[(4-Methylphenyl)sulfonyl][4-(sulfoamino)benzoyl]amino}ethyl)phenyl]sulfamic acid; (4-{2-[Benzoyl-(toluene-4-sulfonyl)-amino]-ethyl}-phenyl)sulfamic acid; [4-(2-{*tert*-Butoxycarbonyl}[(3-fluoro-4-methylphenyl)sulfonyl]amino}ethyl)phenyl]sulfamic acid; [4-(2-{(*tert*-Butoxycarbonyl}[(3-fluorophenyl)sulfonyl]amino)ethyl}phenyl]sulfamic acid; [4-(2-{(*tert*-Butoxycarbonyl}[(2-fluorophenyl)sulfonyl]amino)ethyl}phenyl]sulfamic acid; {4-[2-(Toluene-4-sulfonylamino)-ethyl]-phenyl}-sulfamic acid; [4-(2-Benzenesulfonylamino-ethyl)-phenyl]-sulfamic acid; [4-(2-Methanesulfonylamino-ethyl)-phenyl]-sulfamic acid; [4-(2-Methanesulfonylamino-ethyl)-phenyl]-sulfamic acid; {4-[2-(4-Methoxy-benzenesulfonylamino)-ethyl]-phenyl}-sulfamic acid; (S)-[4-(2-Dibenzylamino-2-methylcarbamoyl-ethyl)-phenyl]-sulfamic acid; (S)-{4-[2-(Acetyl-benzyl-amino)-2-methylcarbamoyl-ethyl]-phenyl}-sulfamic acid; (S)-2-(Benzyl-*tert*-butoxycarbonyl-amino)-3-(4-sulfoamino-phenyl)-propionic acid methyl ester; (S)-Benzyl-[1-methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid methyl ester; (S)-Benzyl-[1-methylcarbamoyl-2-(4-sulfoamino-phenyl)-ethyl]-carbamic acid *tert*-butyl ester; N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-N-methyl-L-4-sulfoamino-phenylalaninamide; N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-N-methyl-L-4-sulfoamino-phenylalaninamide; N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-4-sulfoamino-phenylalaninamide; N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-N-methyl-L-4-sulfoamino-phenylalaninamide; N-[(1,1-dimethylethoxy)carbonyl]-L-valinyl-N-methyl-L-4-sulfoamino-phenylalaninamide; N-[(1,1-dimethylethoxy)carbonyl]-L-glutamyl-N-methyl-L-4-sulfoamino-phenylalaninamide; N-[(1,1-dimethylethoxy)carbonyl]-L-asparaginyl-N-methyl-L-4-sulfoamino-phenylalaninamide; N-{1-[1-Pentylcarbamoyl-2-(4-sulfoamino-phenyl)-ethylcarbamoyl]-2-phenyl-ethyl}-succinamic acid; N-{1-L-[1-Pentylcarbamoyl-2-(4-sulfoamino-phenyl)-ethylcarbamoyl]-2-L-phenyl-ethyl}-carbamic acid *tert*-butyl ester; (S)-2-*tert*-Butoxycarbonylamino-3-(4-sulfoamino-phenyl)-propionic acid methyl ester; [2-(4-Sulfoamino-phenyl)-ethyl]-carbamic acid *tert*-butyl ester; [4-(2-Diphenylacetyl-amino-ethyl)-phenyl]-sulfamic acid; and (S)-[4-(3-Acetyl-1,2,2-trimethyl-5-oxoimidazolidin-4-ylmethyl)-phenyl]-sulfamic acid; and N-[(1,1-dimethylethoxy)carbonyl]-L-prolinyl-N-methyl-L-4-sulfoamino-phenylalaninamide.

19. A method of treating a protein tyrosine phosphatase (PTPase) mediated disorder comprising administering a compound of Claim 1 to a subject in need thereof.

20. The method of Claim 19, wherein the disorder is selected from the group consisting of atherosclerotic cardiovascular disease including peripheral vascular disease, coronary disease and cerebral vascular disease; heart failure; hypertension; diabetes (Type 1 or Type 2); skeletal muscle atrophy; osteoporosis; obesity; disorders of the gastrointestinal tract including inflammatory bowel disease and ulcer; wound healing and wrinkle repair/prevention; hair loss and cancer.

21. A pharmaceutical composition comprising:

- a) safe and effective amount of a compound of Claim 1; and
- b) a pharmaceutically-acceptable carrier.